Ependymoma

Ependymoma is a tumor arising from the ependymal cells that line the ventricles of the brain and the central canal of the spinal cord. It is a relatively rare form of central nervous system (CNS) tumor and occurs in both adults and children. Ependymomas are classified by grade into three main groups: anaplastic ependymoma, low-grade ependymoma, and myoependymoma. The clinical manifestations of this disease vary depending on the location of the tumor and may include neurological symptoms such as headaches, seizures, hearing or vision loss, and changes in motor function. The study of ependymoma is an important part of oncology and neurosurgery, which requires a multifactorial approach to diagnosis and treatment.

History of the disease and interesting historical facts

The history of the study of ependymomas dates back to the late 19th century, when such tumors were first described thanks to the efforts of anatomists and pathologists. One of the first to present systematic data on these tumors was the German pathologist Rudolf Virchow in 1858. During the 20th century, research in the field of neuronal pathology has significantly deepened, which has allowed for a better understanding of the biological characteristics of ependymomas and the causes of their occurrence. In the 1990s, the classification of brain tumors was standardized, where ependymomas received a separate place. Interestingly, in the 1980s, there was an increase in scientific interest in molecular genetics, which opened up new horizons in understanding the genetic and molecular mechanisms underlying this disease.

Epidemiology

Ependymomas account for approximately 2-4% of all primary tumors of the brain and spinal cord and are observed in both children and adults. According to statistics, approximately 2-3 cases of ependymoma per 100,000 people are registered annually worldwide. These tumors most often occur in young children, representing 5-10% of all central nervous system tumors in this age group. In adults, ependymomas are less common, with the peak incidence occurring at the age of 30-40 years. There is no established gender predisposition to the disease, but a slightly higher incidence is observed in boys. Ependymomas often arise in the posterior cranial fossa in children and in the spinal canal in adults, which causes differences in clinical manifestations.

Genetic predisposition to this disease

Studies show that genetic mutations or chromosomal abnormalities may be found in some patients with ependymomas. The most common alterations are in genes involved in the cell cycle, apoptosis, and cell growth regulation. Some genetic syndromes, such as Neifertiti syndrome and tuberous sclerosis syndrome, are known to increase the risk of developing ependymomas. Recent studies have also found mutations in genes such as NF2 and TP53, suggesting possible molecular mechanisms that contribute to the development of this tumor. A combination of genetic predisposition and environmental risk factors may play a role in the pathogenesis of the disease.

Risk factors for the development of this disease

Risk factors associated with the development of ependymomas include both physical and chemical exposures. Physical exposures include exposure to ionizing radiation, such as during treatment of other tumors, and brain trauma. Chemical exposures that cause DNA damage may include certain carcinogens such as formaldehyde and lead. Infectious agents such as viruses have also been suggested to contribute to the development of CNS tumors, but this requires further study. Other possible associated factors include a family history of cancer and genetic predispositions.

Diagnosis of this disease

The main symptoms of ependymoma can vary depending on its location and include:

• Headaches that may progress over time;
• Visual or hearing impairment;
• Convulsions;
• Impaired coordination and motor activity;
• Changes in behavior or cognitive impairment.

Laboratory tests may include blood tests to assess the patient’s overall health and rule out other pathologies. Radiological examinations such as magnetic resonance imaging (MRI) and computed tomography (CT) are the main imaging methods used to visualize the tumor, assess its size and location. Other diagnostics may include neuropsychological tests to assess cognitive function. Differential diagnosis requires exclusion of other CNS tumors such as gliomas and meningiomas, as well as metastatic lesions.

Treatment

Treatment of ependymoma depends on its location, size, degree of malignancy and the general condition of the patient. The main approaches to treatment include:

• Surgical removal of the tumor, which is the preferred treatment method;
• Radiation and chemotherapy, which may be used in combination with surgery to reduce the risk of recurrence;
• Palliative care to improve quality of life in patients with inoperable forms;
• General medical supervision taking into account possible side effects.

Pharmacological treatment may include the use of steroids to reduce swelling around the tumor and symptomatic treatments such as anticonvulsants. Surgical treatment aims to remove as much of the tumor as possible while minimizing damage to adjacent structures.

List of medications used to treat this disease

The use of drugs in the treatment of ependymoma is mainly aimed at symptomatic effects and supporting the general condition of the patient. These include:

• Dexamethasone - to reduce swelling;
• Lamotrigine – to control seizures;
• Paclitaxel - as part of chemotherapy;
• Gemcitabine - for inoperable forms;
• Carboplatin – for the treatment of recurrent cases.

Disease monitoring

Monitoring of the patient's condition after treatment of ependymoma includes regular imaging studies (MRI or CT) to detect possible tumor recurrence. Control stages are carried out every 3-6 months for the first two years after treatment, and then with an extension of the period up to one year. The prognosis depends on the stage of the disease and the completeness of the tumor removal. Complications may include neurological deficits resulting from surgery, as well as side effects of chemotherapy and radiation therapy.

Age-related features of the disease

Ependymomas have different clinical manifestations depending on the age of the patient. In children, this tumor often manifests as a ventricular block syndrome leading to hydrocephalus, while in adults, localized neuropathology associated with a specific area of the brain is more common. In infancy and childhood, ependymomas are usually more aggressive and prone to metastasis, while after the age of 40, tumors may show signs of slower growth, but with a higher risk of recurrence after surgery.

Questions and Answers

• What is ependymoma? Ependymoma is a tumor that originates from the ependymal cells lining the ventricles of the brain and spinal canal.
• What are the main symptoms of ependymoma? Symptoms may include headaches, seizures, vision and hearing problems, behavioral changes, and movement problems.
• How is ependymoma diagnosed? Diagnosis includes radiological examinations (MRI, CT), laboratory tests and neuropsychological assessments.
• How is ependymoma treated? Treatment includes surgery, radiation and chemotherapy, and symptomatic therapy.
• What is the prognosis for a patient with ependyma? The prognosis depends on the stage of the disease, whether the tumor was successfully removed and the presence of relapses, as well as the general condition of the patient.

Advice from Dr. Oleg Korzhikov

Dr. Oleg Korzhikov emphasizes the importance of early diagnosis and active monitoring of health. He emphasizes that following doctor's orders and regular examinations will help to identify relapses of the disease at an early stage. "It is also necessary to discuss with the doctor potential side effects of treatment and options for minimizing them," the specialist warns. It is important to actively inform your doctor about any new symptoms and changes in your health, as this will help to promptly adjust the treatment plan. Take care of your health and take care of timely medical examinations.